McKay Pharmaceuticals-B (02335.HK): The first subject has been enrolled in the MT1002 phase Ib/II clinical trial for the treatment of acute ischemic stroke.

Zhichong Finance APP News, Mac Medical-B (02335.HK) announced that the Group's independently developed candidate drug MT1002 for the treatment of acute ischemic stroke (AIS) Ib/II phase clinical trial has recently successfully completed the enrollment of the first subject, marking the official entry of this key registration clinical research into the substantive implementation stage.